Zurich (awp) – The Swiss Stock Exchange retained its gains from the start of the session on Tuesday as midday approached, thus making up part of the delay accumulated the day before. The results season was taking shape in Switzerland, notably with the preliminary performance of Lindt&Sprüngli, before a series of indications on inflation in the United States.
Uncle Sam’s country must first take stock of its production and import prices (PPI) at the start of the afternoon, before delivering its official inflation statistics (CPI) on Wednesday. .
“Good indications on inflation today and tomorrow could propel the indices to new highs. But the inauguration of the new American president on Monday is likely to completely reshuffle the cards, depending on the themes that the Republican will pin down. “its priorities agenda,” observes Jürgen Molnar, strategist at RoboMarket.
Around 11:00 a.m., the Swiss Market Index (SMI) gained 0.49% to 11,758.53 points, the Swiss Leader Index (SLI) 0.59% to 1,943.55 points and the Swiss Performance Index (SPI) 0.55 % at 15,680.52 points. Of the thirty largest capitalizations, only three declined and two stagnated.
The industrial chocolatier Lindt&Sprüngli (good +5.7%) was at the top of the index, which at dawn delivered a more convincing first glimpse of its 2024 performance than expected.
Following at some distance were the mouse giant Logitech (+2.3%) and then the hearing aid supplier Sonova (+1.7%), which confirmed its short-term roadmap during a investor conference.
The drugs and biosimilars juggernaut Sandoz (-0.3%, bottom) tried the same exercise, with more mixed success. The Verniolo-Winterthur chemist Givaudan and the pharmaceutical heavyweight Novartis (-0.1% each) completed the group.
Asset manager Partners Group (+0.9%) benefited moderately from a price target increase by Goldman Sachs as a preamble to the presentation of the annual evolution of its assets under management (AuM), scheduled for the evening .
The food liner Nestlé (+0.1%) and the pharmaceutical juggernaut Roche (good +0.7%) supported the recovery.
In the broader market, Temenos (+8.5%) clearly stood out from the crowd. The Geneva-based banking software publisher issued a positive warning on results for the past financial year the evening before. However, it was preceded by the Santhera laboratory (+8.6%) which saw a Scottish regulator recommend its treatment against myopathy, as well as the biotech Idorsia (+9.4%), based on negotiations with its creditors.
The dermato-cosmetic laboratory Galderma (+1.0) claims encouraging intermediate study results around the use of aesthetic injectables on people who have experienced significant medically induced weight loss.
The chip producer U-blox (-0.1%) has decided to abandon its loss-making cellular activities, failing to find a buyer. The decision involves value adjustments of nearly 100 million Swiss francs between the last part of 2024 and the first of 2025, as well as the elimination of some 200 jobs around the world.
The specialty chemist Clariant (-1.0%) was implicated by the German sector behemoth BASF in a cartel case. An implication that the Rhine group disputes.
jh/vj/rr/jh
